Quote:
In summary, based on the totality of the trials and epidemiologic evidence presented in this review along with the preliminary findings of the Unitaid/WHO meta-analysis of treatment RCTs and the guideline recommendation from the international BIRD conference, ivermectin should be globally and systematically deployed in the prevention and treatment of COVID-19.
Quote:
Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.
American Journal of Therapeutics 2021 May-Jun; 28(3): e299e318.
Published online 2021 Apr 22.
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19Pierre Kory, MD,1,* Gianfranco Umberto Meduri, MD,2 Joseph Varon, MD,3 Jose Iglesias, DO,4 and Paul E. Marik, MD5
Author information Copyright and License information Disclaimer
1Front-Line Covid-19 Critical Care Alliance, Madison, WI;
2Memphis VA Medical CenterUniversity of Tennessee Health Science Center, Pulmonary, Critical Care, and Research Services, Memphis, TN;
3University of Texas Health Science Center, Critical Care Service, Houston, TX;
4Department of Medicine, Hackensack School of Medicine, Seton Hall, NJ; and
5Eastern Virginia Medical School, Division of Pulmonary and Critical Care, Norfolk, VA.
Gianfranco Umberto Meduri: ude.cshtu@irudemg; Joseph Varon: ten.oohay@noravhpesoj; Jose Iglesias: moc.liamg@32saiselgij; Paul E. Marik: gro.enilnokiram@luap
*Address for correspondence: Pierre Kory, MD, MPA, Front-Line Covid-19 Critical Care, 2002 L St NW, Suite 500, Washington, D.C 20036. E-mail: ten.ccclf@yrokp